{
    "clinical_study": {
        "@rank": "36754", 
        "arm_group": [
            {
                "arm_group_label": "ZGN-440 sterile diluent", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks."
            }, 
            {
                "arm_group_label": "1.2 mg ZGN-440 for injectable suspension", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks."
            }, 
            {
                "arm_group_label": "1.8 mg ZGN-440 for injectable suspension", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for\n      certain doses of beloranib in obese subjects with Prader-Willi Syndrome."
        }, 
        "brief_title": "An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Obesity", 
            "Over-weight", 
            "Prader-Willi Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Prader-Willi Syndrome", 
                "Overweight"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of Prader-Willi Syndrome due to chromosome 15 micro-deletion,\n             maternal uniparental disomy, or imprinting defect\n\n          -  BMI \u226525 kg/m2\n\n          -  Type 2 diabetes mellitus is allowed\n\n          -  Subject must agree to stay at the group home or under supervision of the group home\n             or site staff (i.e. no home visits) for the duration of the study\n\n          -  Stable body weight during the past 3 months, except for during home visits\n\n        Exclusion Criteria:\n\n          -  Use of weight loss agents in the past 3 months\n\n          -  Type 1 diabetes mellitus\n\n          -  Current or anticipated chronic use of narcotics or opiates"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818921", 
            "org_study_id": "ZAF-211"
        }, 
        "intervention": [
            {
                "arm_group_label": "ZGN-440 sterile diluent", 
                "description": "ZGN-440 sterile diluent/placebo", 
                "intervention_name": "ZGN-440 sterile diluent", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ZGN-440 sterile diluent", 
                    "Placebo"
                ]
            }, 
            {
                "arm_group_label": "1.2 mg ZGN-440 for injectable suspension", 
                "description": "1.2 mg beloranib", 
                "intervention_name": "1.2 mg ZGN-440 for injectable suspension", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ZGN-440 for injectable suspension", 
                    "ZGN-440", 
                    "ZGN-433", 
                    "Beloranib"
                ]
            }, 
            {
                "arm_group_label": "1.8 mg ZGN-440 for injectable suspension", 
                "description": "1.8 mg beloranib", 
                "intervention_name": "1.8 mg ZGN-440 for injectable suspension", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ZGN-440 for injectable suspension", 
                    "ZGN-440", 
                    "ZGN-433", 
                    "Beloranib"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Beloranib", 
            "ZGN-440", 
            "ZGN-440 for injectable suspension", 
            "ZGN-433"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32610-0296"
                }, 
                "name": "University of Florida"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate Weight Reduction, Food-related Behavior, Safety, and Pharmacokinetics Over 4 Weeks Followed by Optional 4-Week Open-Label Extension", 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Jennifer Miller, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percent change in body weight from baseline to the end of the randomized dosing period.", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818921"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in body weight (kg) from baseline to the end of the randomized dosing period", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Change in hyperphagia behavior, drive, and severity score (total score) from baseline to the end of the randomized dosing period using the PWS Hyperphagia Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Zafgen, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zafgen, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}